Jennison Associates
TVTX icon

Jennison Associates’s Travere Therapeutics TVTX Stock Holding History

Jennison Associates’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-1,000,000
Closed -$19.3M – 660
2015
Q4 		$19.3M Hold
1,000,000
– – 0.02% 429
2015
Q3 		$20.3M Buy
+1,000,000
New +$29.6M 0.02% 434

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jennison Associates's TVTX Position: Q1 2026 in Review

Jennison Associates sold out of Travere Therapeutics (TVTX) in Q1 2026, closing a stake of 256,335 shares — an estimated $9.79M sold.

Jennison Associates first reported a position in TVTX in Q1 2014 and held it in 26 quarters. The position peaked at $98.4M in Q2 2015. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Jennison Associates reported no remaining Travere Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Jennison Associates sold 256,335 Travere Therapeutics shares in Q1 2026, an estimated $9.79M.
  • Jennison Associates first reported a position in Travere Therapeutics in Q1 2014 and held it in 26 quarters.
  • Jennison Associates's Travere Therapeutics position peaked at $98.4M in Q2 2015.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Jennison Associates's 13F filing for Q1 2026, filed 6 May 2026.